Literature DB >> 22771869

Responding to medical emergencies: system characteristics under examination (RESCUE). A prospective multi-site point prevalence study.

Tracey K Bucknall1, Daryl Jones, Rinaldo Bellomo, Margaret Staples.   

Abstract

AIM: To determine the point-prevalence of patients fulfilling hospital-specific Medical Emergency Team (MET) criteria and their subsequent outcomes.
METHOD: Inpatients from 10 hospitals with established METs were enrolled for a prospective, point-prevalence study. If MET criteria were present during a set of vital signs, the ward manager was notified. MET activations, unplanned Intensive Care Unit (ICU) admissions, cardiac arrests, Limitations of Medical Treatment (LOMT), hospital discharge and follow-up mortality data were collected.
RESULTS: Of 1688 patients recruited, 3.26% (n=55) fulfilled MET criteria in a single set of vital signs. None of the 55 received MET review within 30 min of notification, 2 (3.6%) had MET review within the next 24h, none experienced cardiac arrests or unplanned ICU admissions during the follow-up period, and 13 (23.6%) had a LOMT order prior to fulfilling MET criteria. In-hospital mortality was significantly higher for patients fulfilling MET activation criteria (9.1%) compared to those that did not (2.6%; p=0.005, RR=2.95; 95% confidence interval (CI) 1.22-7.15), as was mortality at 30 days (RR=2.64; 95% CI 1.37-5.11) and 60 days (RR=1.94; 95% CI 1.11-3.40). The 30 day mortality in patients without an LOMT order was similar to patients without MET criteria (RR=0.94; 95% CI 0.24-3.7).
CONCLUSIONS: Approximately 1 in 30 hospitalised patients fulfilled MET criteria during data collection. The presence of MET criteria was associated with increased hospital, 30 and 60 day mortality, although much of this increased mortality seemed to be due to issues around end-of-life care. Despite ward manager notification, subsequent MET activation occurred infrequently in these hospitals with established METs. Further research is needed to assess factors that influence staff initiation of a MET call.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22771869     DOI: 10.1016/j.resuscitation.2012.06.015

Source DB:  PubMed          Journal:  Resuscitation        ISSN: 0300-9572            Impact factor:   5.262


  5 in total

Review 1.  Early warning systems and rapid response systems for the prevention of patient deterioration on acute adult hospital wards.

Authors:  Jennifer McGaughey; Dean A Fergusson; Peter Van Bogaert; Louise Rose
Journal:  Cochrane Database Syst Rev       Date:  2021-11-22

2.  Trends in the national early warning score are associated with subsequent mortality - A prospective three-centre observational study with 11,331 general ward patients.

Authors:  Eetu Loisa; Antti Kallonen; Sanna Hoppu; Joonas Tirkkonen
Journal:  Resusc Plus       Date:  2022-05-21

3.  Multi-Tiered Observation and Response Charts: Prevalence and Incidence of Triggers, Modifications and Calls, to Acutely Deteriorating Adult Patients.

Authors:  Arthas Flabouris; Savvy Nandal; Luke Vater; Katerina Flabouris; Alice O'Connell; Campbell Thompson
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

4.  Effect of a newly designed observation, response and discharge chart in the Post Anaesthesia Care Unit on patient outcomes: a quasi-expermental study in Australia.

Authors:  Maryann Street; Nicole M Phillips; Mohammadreza Mohebbi; Bridie Kent
Journal:  BMJ Open       Date:  2017-12-03       Impact factor: 2.692

5.  Prioritising Responses Of Nurses To deteriorating patient Observations (PRONTO) protocol: testing the effectiveness of a facilitation intervention in a pragmatic, cluster-randomised trial with an embedded process evaluation and cost analysis.

Authors:  Tracey K Bucknall; Gill Harvey; Julie Considine; Imogen Mitchell; Jo Rycroft-Malone; Ian D Graham; Mohammadreza Mohebbi; Jennifer Watts; Alison M Hutchinson
Journal:  Implement Sci       Date:  2017-07-11       Impact factor: 7.327

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.